CLYM
NASDAQ
$12.22
Eliem Therapeutics Inc (CLYM)
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $20.93 (+71.28%)
Market Cap
$663M
Free Cash Flow Yield
-8.07%
Beta (5Y)
1.36
Price Chart
Valuation
Market Cap$663M
P/B5.12
Profitability
EBITDA-$60M
EPS-$0.97
Financial Health
Free Cash Flow Yield-8.07%
Growth & Risk
Beta (5Y)1.36
Sharpe Ratio2.59